Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2011

View Archived Issues

Theophylline improves motor function after stroke

Vitae and Boehringer Ingelheim claim new 11-beta-HSD1 inhibitors

New protein glutamine gamma-glutaminyltransferase 2 inhibitors presented

Verona Pharma provides update on clinical development programs

Sylentis gains approval in Spain to conduct trials of RNAi therapy SYL-1001

Mologen to investigate DNA immunomodulator MGN-1703 in lung cancer

Interim first-in-human data suggest MK-1496 is active against solid tumors

First-in-human phase 0/Ia SM-101 study in healthy volunteers completed

Abagovomab does not prolong survival of patients with ovarian cancer in MIMOSA trial

Liraglutide added to insulin shows promise in treating type 1 diabetes

Merck KGaA prepares novel PI3K inhibitors

Mellitech researchers disclose new insulin secretagogues

GSK presents new serine/threonine-protein kinase B-raf inhibitors

SPX-106 with D-tagatose significantly reduces cholesterol and triglycerides in mice

Grifols completes acquisition of Talecris Biotherapeutics

Evotec and Active Biotech form medicinal chemistry collaboration

GE Healthcare and ImaginAb to develop PET imaging agents based on antibody fragments

NovaDel Pharma files IND with FDA for sildenafil oral spray

AIM Therapeutics begins first-in-human phase I trial of AIM-102

Ferrer files MAA with EMA for tesamorelin

Plexxikon provides update on vemurafenib development program

Adolor completes enrollment in phase II ADL-5945 program

Seaside Therapeutics begins pivotal phase III STX-209 trial in fragile X syndrome

NICE recommends Ozurdex to treat for macular edema due to retinal vein occlusion

Laureate Biopharmaceutical to manufacture Patrys' lead anticancer product, PAT-LM1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...